New York, October 10, 2024 - PRISM MarketView - There is a reason that Breast Cancer Awareness Month has been recognized every October for the past four decades: 1 in 8 women will be diagnosed with breast cancer in her lifetime, according to the National Cancer Institute. The two biggest risk factors for breast cancer are being a woman and aging. And more than 2 million women are diagnosed with breast cancer each year, based on World Health Organization reports.
Breast Cancer Awareness Month is an international campaign to promote early detection and awareness of breast cancer, which has a 99% five-year relative survival rate when found in its earliest stages, according to National Breast Cancer Foundation. Mammograms and regular doctors’ visits have bolstered rates of early detection in addition to notable research.
Advances in breast cancer treatment are saving lives
Breast cancer is no longer a death sentence.
Recent developments in treatment include the use of immunotherapy to treat triple-negative breast cancer – an aggressive form of cancer – and potentially other cancers as well. In addition, antibody-drug conjugates are being increasingly used to support improved survival rates for those with metastatic breast cancer, which means it has spread beyond the breast to the brain, liver, lungs or other areas of the body. Two significant antibody-drug conjugates showing effective results are sacituzumab govitecan (Trodelvy) and trastuzumab deruxtecan (T-DXd; Enhertu).
In addition, genetic testing advancements are helping physicians better customize treatments for each patient. Ongoing trials are investigating circulating tumor DNA’s [ctDNA] potential role in breast cancer, and precision medicine that has pinpointed specific mutations that respond well to targeted therapies, which often come with fewer side effects than traditional chemotherapy.
These advancements lead to better treatments, better quality of life and better survival rates for breast cancer patients.
Companies in the PRISM MarketView Spotlight:
Anixa Biosciences (NASDAQ: ANIX) – Anixa is developing a breast cancer vaccine targeting “retired” proteins, such as α-lactalbumin, linked to triple-negative breast cancer (TNBC). Currently in Phase 1 trials in collaboration with Cleveland Clinic, the vaccine has shown early positive immune responses and safety. Further data will be presented in November 2024 at the SITC Annual Meeting. As it relates to its upcoming Phase 2 trial, Anixa recently provided that they will evaluate the efficacy of the vaccine administered in the neoadjuvant (before surgery) setting, in combination with chemotherapy and Keytruda (pembrolizumab). The goal of neoadjuvant therapy is to reduce tumor burden and to prevent tumor recurrence with the intent to improve survival. This will be expected to begin in 2025 and last approximately 2-3 years. As of June 30, 2024, the company has zero debt and cash position of $23M.
Anixa Biosciences - Prism MarketView
Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine
Read More
Atossa Therapeutics (NASDAQ: ATOS) – Atossa’s lead asset, (Z)-endoxifen, is in Phase 2 trials, aiming to reduce breast cancer risk by lowering breast tissue density and preventing recurrence. The Karisma-Endoxifen study, with data expected in Q4 2024, is investigating its potential to reduce mammographic breast density. Atossa is also supporting the SMART study, which could lead to a Phase 3 trial for breast cancer prevention. From a financial perspective, ATOS shares have traded up over 45% YTD, the company recently joined the Russell 3000 and Atossa ended its second quarter of 2024 with $79.5M in cash and cash equivalents and no debt.
IceCure Medical (NASDAQ: ICCM) – IceCure develops cryoablation systems for treating benign and cancerous tumors, including breast cancer. Its ProSense® system offers a minimally invasive alternative to surgery. IceCure recently presented promising results at the 2024 European Society of Breast Imaging (EUSOBI) Conference, highlighting its potential to improve patient outcomes. In the company’s most recent quarterly financial release, it was reported that the ProSense® System and probe sales saw 20% growth for the first half of 2024, reflecting continued adoption in the US and other global markets.
IceCure Medical Ltd - Prism MarketView
IceCure Medical is a medical device company innovating cryotherapy solutions to treat benign & malignant tumors with our liquid nitrogen based ProSense™ Cryoablation System for women’s health and interventional oncology. #freezecancernotyourlife Founded in 2006 to advance the treatment of cancerous tumors, our FDA-cleared and CE-marked ProSense™ Cryoablation System utilizes liquid nitrogen to generate ultra-cold temperatures
Read More
Immutep Limited (NASDAQ: IMMP) – Immutep is a clinical-stage company pioneering LAG-3 immunotherapies for cancer and autoimmune diseases. The company recently completed enrollment in a Phase II trial investigating eftilagimod alpha (efti) in combination with paclitaxel for breast cancer. The trial aligns with the FDA’s Project Optimus initiative to optimize dosage regimens. Additionally, the company recently received a $3.6M R&D tax incentive from the French government and qualifies for cash rebates from the Australian government’s R&D tax incentive program. The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and IMP761.
Olema Pharmaceuticals (NASDAQ: OLMA) – Olema’s lead candidate, palazestrant (OP-1250), is in Phase 3 trials for ER+/HER2- metastatic breast cancer. Palazestrant, a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), has shown promising efficacy and favorable tolerability in trials, earning FDA Fast Track designation. As of June 30, 2024, the company has $239M in cash, cash equivalents and marketable securities.
Processa Pharmaceuticals (NASDAQ: PCSA) – Processa is developing NGC-Cap, a next-generation chemotherapy agent, in a Phase 2 trial for metastatic breast cancer. The trial compares NGC-Cap to standard monotherapy capecitabine and aims to determine the optimal dosage with fewer side effects, in line with the FDA’s Project Optimus initiative. Interim results are expected in mid-2025.
These companies are leading the charge in developing new treatments, offering hope to breast cancer patients worldwide.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities